William Blair Predicts Reduced Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities research analysts at William Blair lowered their Q3 2025 EPS estimates for shares of Krystal Biotech in a report released on Friday, October 10th. William Blair analyst S. Corwin now expects that the company will post earnings per share of $1.11 for the quarter, down from their prior forecast of $1.14. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s FY2025 earnings at $5.16 EPS.

Other analysts also recently issued reports about the stock. Bank of America dropped their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Citigroup restated a “neutral” rating and set a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Chardan Capital dropped their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a “buy” rating on the stock in a report on Friday, August 22nd. Finally, HC Wainwright restated a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $209.00.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $184.74 on Monday. The company has a market capitalization of $5.35 billion, a P/E ratio of 37.55 and a beta of 0.64. The company’s 50 day moving average price is $156.47 and its two-hundred day moving average price is $150.78. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%.

Insider Activity

In other news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AdvisorNet Financial Inc bought a new position in shares of Krystal Biotech in the third quarter valued at $30,000. Voya Investment Management LLC grew its stake in shares of Krystal Biotech by 46.7% in the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after buying an additional 29,915 shares in the last quarter. City Center Advisors LLC bought a new position in shares of Krystal Biotech in the third quarter valued at $300,000. GAMMA Investing LLC grew its stake in shares of Krystal Biotech by 74.4% in the third quarter. GAMMA Investing LLC now owns 497 shares of the company’s stock valued at $88,000 after buying an additional 212 shares in the last quarter. Finally, Caldwell Trust Co bought a new position in shares of Krystal Biotech in the second quarter valued at $34,000. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).